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Abstract
Background: The Diabetes Prevention Program (DPP) was a randomized, controlled clinical trial. It demonstrated
that among high-risk individuals with impaired glucose tolerance, diabetes incidence was reduced by 58 % with
lifestyle intervention and 31 % with metformin compared to placebo. During the Diabetes Prevention Program
Outcomes Study (DPPOS), all DPP participants were unmasked to their treatment assignments, the original lifestyle
intervention group was offered additional lifestyle support, the metformin group continued metformin, and all three
groups were offered a group-implemented lifestyle intervention. Over the 10 years of combined DPP/DPPOS
follow-up, diabetes incidence was reduced by 34 % in the lifestyle group and 18 % in the metformin group
compared to placebo. The purpose of this article is to review and synthesize analyses published by the DPP/DPPOS
Research Group that have described the cost-effectiveness of diabetes prevention.
Methods: We describe the resource utilization and costs of the DPP and DPPOS interventions, the costs of non-
intervention-related medical care, the impact of the interventions on diabetes progression and quality-of-life, and
the cost-effectiveness of the interventions from health system and societal perspectives. Cost-effectiveness analyses
were performed with a 3-year time horizon using DPP data, a lifetime time horizon that simulated 3-year DPP data,
and a 10-year time horizon using combined DPP/DPPOS data.
Results: Although more expensive than the placebo intervention, the greater costs of the lifestyle and metformin
interventions were offset by reductions in the costs of nonintervention-related medical care. Every year after
randomization, quality-of-life was better for participants in the lifestyle intervention compared to those in the
metformin or placebo intervention. In both the simulated lifetime analysis and the 10-year within trial economic
analysis, lifestyle and metformin were extremely cost-effective (that is, improved outcomes at a low incremental cost)
or even cost-saving (that is, improved outcomes and reduced total costs) compared to the placebo intervention.
Conclusions: The implementation of diabetes prevention programs in high-risk individuals will result in important
health benefits and represents a good value for money.
Trial registration: NCT00004992 (DPP) and NCT00038727 (DPPOS).
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Introduction
The Diabetes Prevention Program (DPP) was a multi-
center clinical trial designed to determine whether mod-
est weight loss through dietary changes and increased
physical activity or treatment with the oral antihypergly-
cemic medication metformin could delay or prevent the
development of type 2 diabetes in high-risk individuals
[1]. The DPP enrolled 3234 participants with glucose in-
tolerance who were at least 25 years of age and had a
body mass index of 24 kg/m2 or higher (22 kg/m2 in
Asian-Americans). Mean age of participants was 51 years
and mean BMI was 34.0 kg/m2. Sixty-eight percent of
participants were women and 45 % were members of
minority groups.
The goals for participants randomized to the intensive
lifestyle intervention were to achieve and maintain a
weight reduction of at least 7% of initial body weight
through a low-calorie, low-fat diet and physical activity
of moderate intensity, such as brisk walking for at least
150 min per week [2]. A 16-lesson core curriculum ad-
dressing diet, physical activity, and behavior modification
was implemented to help participants achieve these
goals. The curriculum, taught by case managers on a
one-to-one basis during the first 24 weeks after enroll-
ment, was flexible, culturally sensitive, and individualized.
Subsequent individual sessions (usually monthly) and
group sessions were designed to reinforce the behavioral
changes.
The medication interventions (metformin and placebo)
were initiated at a dose of 850 mg taken orally once a
day [3]. At one month, the dose of metformin or placebo
was increased to 850 mg twice daily unless gastrointes-
tinal symptoms warranted a longer titration period. Par-
ticipants were seen by case managers and adherence to
the treatment regimen was reinforced quarterly. The
standard lifestyle recommendations for the medication
groups were provided in an annual 20 to 30 min individ-
ual session. The DPP demonstrated that compared to
the placebo intervention, the intensive lifestyle interven-
tion reduced the incidence of type 2 diabetes by 58 %,
and the metformin intervention reduced the incidence
of type 2 diabetes by 31 % over 3 years [1].
At the conclusion of DPP, participants were enrolled
in the Diabetes Prevention Program Outcomes Study
(DPPOS). DPPOS was designed to assess the long-term
effects of the interventions on health [4]. During
DPPOS, participants originally randomized to the life-
style and metformin interventions were encouraged to
continue those interventions and all participants were
offered a group lifestyle intervention. The incidence of
diabetes during the 10-year average follow-up after DPP
randomization was reduced by 34 % in those initially
randomized to lifestyle and 18 % in those initially ran-
domized to metformin compared to placebo [4].
To date, we have reported the resources used and the
costs of care, and the cost-effectiveness of the lifestyle and
metformin interventions relative to the placebo interven-
tion over the 3 year timeframe of the randomized con-
trolled clinical trial [5, 6]. We also used data collected
during the 3 years of the DPP and a computer model to
simulate the cost-effectiveness of the interventions over a
lifetime [7]. Although we [7] and others [8, 9] suggested
that the DPP interventions would be cost-effective or even
cost-saving over the long term, one analysis suggested that
they might be too expensive to be routinely implemented
[10]. To better address the longer-term cost-effectiveness
of the DPP interventions, we subsequently performed a
within-trial analysis spanning the combined 10-years of
DPP/DPPOS [11]. In this report, we synthesize and dis-
cuss the results of these published reports.
Review
Methods
We described the direct medical costs, direct non-
medical costs, and indirect costs incurred by participants
in the lifestyle, metformin, and placebo intervention
groups during DPP [5] and DPPOS [11]. In general, we
calculated the direct medical costs of the interventions
by assessing resources used and applying standard unit
costs [5]. We excluded from the analysis the resources
used and costs of developing the interventions and col-
lecting outcomes to evaluate the interventions [5]. The
direct costs of medical care received outside the study
and indirect costs were determined annually from pa-
tient self-report. Direct non-medical costs were assessed
once during DPP and once during DPPOS, and costs
were annualized. All costs were adjusted to 2000 or 2010
U.S. dollars using the Consumer Price Index and the
Medical Consumer Price Index.
In our analyses, we adopted two separate perspectives:
the perspective of a large health system and the perspec-
tive of society. In the analyses that adopted the perspec-
tive of a health system, we considered the direct medical
costs of the DPP/DPPOS interventions and the direct
medical costs of care received outside the study. In the
analyses adopting the perspective of society, we consid-
ered direct medical costs, direct non-medical costs, and
indirect costs.
Direct medical costs represent expenditures for med-
ical services and products that are usually paid by health
systems. These costs include the costs of hospital days,
emergency room visits, urgent care (immediate care for
injuries and illnesses in a medical facility outside of a
traditional emergency room) visits, outpatient visits, calls
to providers, supplies, laboratory tests, and prescription
medications. In estimating direct medical costs, we con-
sidered the costs of the interventions and the costs of
non-intervention-related medical care received outside
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the DPP/DPPOS. Direct non-medical costs represent ex-
penditures arising as a result of medical treatment or ill-
ness but not involving the purchase of medical services
or products. Since these costs do not represent health
care expenditures, they are not usually paid by health
systems. They do, however, represent “out-of-pocket”
costs to patients and costs to society. In DPP/DPPOS,
direct non-medical costs included the value of the time
that participants spent traveling to and attending appoint-
ments, exercising, shopping, and cooking; the costs of ex-
ercise classes, exercise equipment, special foods, and food
preparation items; and the costs of transportation to and
from appointments. Indirect costs are another cost to so-
ciety that arise from illness-related morbidity and mortal-
ity. Indirect costs from morbidity arise from being absent
from work due to medical treatment, illness, or long-term
disability. Indirect mortality costs arise from lost product-
ivity due to premature death.
We performed cost-utility analyses by comparing costs
to outcomes across intervention groups. When an inter-
vention costs less and improves outcomes relative to an
alternative treatment, it is called cost-saving. When an
intervention costs more but improves outcomes relative
to an alternative treatment at a cost per unit outcome
considered to represent a good value for the money
spent, it is termed cost-effective. Outcomes were
expressed in terms of quality-adjusted life-years (QALYs)
[6]. QALYs measure length of life adjusted for quality of
life. Mathematically, QALYs are calculated as the sum of
the product of the number of years of life and the
quality-of-life in each of those years. The numerical
value assigned to quality of life is called a health utility
score. By convention, health utility scores are placed on
a continuum where perfect health is assigned a value of
1.0 and health judged equivalent to death is assigned a
value of 0.0. We assessed health utility scores from the
perspective of the general public using the Self-
Administered Quality of Well-Being Index (QWB-SA)
which was administered to DPP participants annually.
At the end of DPP, we performed a 3-year within trial
economic analysis of the DPP and used a simulation
model to estimate the lifetime cost-effectiveness of the
interventions. The simulation model was originally de-
veloped by the Centers for Disease Control and Preven-
tion and Research Triangle Institute International to
assess the progression from impaired glucose tolerance
to the onset of diabetes to clinically diagnosed diabetes
to diabetes with complications and comorbidities to
death [12]. The model has a Markov structure and in-
cludes annual transition probabilities between disease
states. In addition to disease progression, the model
tracks costs and QALYs. For our analyses, we modified
the model to include data from the DPP on progression,
costs, and quality of life associated with impaired
glucose tolerance; data from the United Kingdom Pro-
spective Diabetes Study (UKPDS) on diabetes progres-
sion, complications, and comorbidities; and new data on
the cost and quality of life associated with diabetes. To
estimate the costs of type 2 diabetes, we applied a multi-
plicative prediction model that estimates annual direct
medical costs according to demographic characteristics,
diabetes treatments, cardiovascular risk factors, and
microvascular and macrovascular complications and co-
morbidities [13]. To estimate health utility scores associ-
ated with type 2 diabetes, we applied an additive
prediction model that estimates health utility scores ac-
cording to demographic characteristics, treatments, and
disease state variables [14]. We then modeled the inter-
ventions as they were implemented in the DPP and pro-
jected year 3 DPP intervention costs, health utility scores,
and intervention effectiveness into the future. We assessed
simulated lifetime costs and QALYs and calculated cost-
effectiveness ratios by dividing incremental costs adjusted
to year 2000 U.S. dollars by incremental QALYs. We
discounted both costs and QALYs at 3 % per year.
In sensitivity analyses, we assessed how robust the re-
sults of the lifetime simulation were to plausible changes
in the inputs. First, we modeled the interventions by age
group. Then, we modeled the interventions as they
might be implemented in routine clinical practice and
assessed the effect of reducing the costs of the interven-
tions. Specifically, we recalculated the cost of the lifestyle
intervention, assuming that the core curriculum, super-
vised activity sessions, and lifestyle group sessions were
administered as a closed group of 10 participants and
that costs were reduced accordingly. Similarly, we recal-
culated the cost of the metformin intervention by using
the cost of generic metformin priced at 25 % the cost of
Glucophage (Bristol-Myers Squibb, Princeton, New
Jersey). Then, we evaluated the impact of reduced par-
ticipant adherence by reducing the effectiveness of the
lifestyle and metformin interventions by 20 % and 50 %
after year 3. Finally, we evaluated the impact of both
reduced costs and reduced effectiveness on lifetime
cost-effectiveness.
In the 10-year within trial economic analysis, we
calculated the total direct medical costs and QALYs
for participants over 10 years according to their ori-
ginal DPP randomization groups and assessed cost-
effectiveness without simulation modeling but using
the empiric data [11]. As a sensitivity analysis, we
again estimated what the cost of the lifestyle interven-
tion might have been if it had been administered dur-
ing DPP in a group format rather than individually
(DPP group lifestyle intervention). Although metfor-
min was implemented with brand name metformin
(Glucophage), we again assumed that it was imple-
mented with generically-priced DPPOS/DPPOS.
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Results
Direct medical costs of the DPP/DPPOS interventions
During both DPP and DPPOS, the lifestyle and metformin
interventions were substantially more expensive than the
placebo intervention. Table 1 shows the undiscounted per
capita direct medical costs of the DPP/DPPOS interven-
tions by intervention group and study year [5]. The costs
of the lifestyle intervention were less during DPPOS than
during DPP because of the change from an individual- to a
group- implemented intervention and because fewer visits
took place [11]. The costs of the placebo intervention were
higher during DPPOS than during DPP because placebo
participants engaged in the group lifestyle intervention
[11]. The cumulative undiscounted per participant cost of
the lifestyle intervention ($4572) was substantially greater
than the metformin intervention ($2881) or the placebo
intervention ($752). The estimated cost of the DPP group
lifestyle intervention ($2995) was approximately one-third
less than that of the lifestyle intervention.
Direct medical costs of care received outside the DPP/DPPOS
interventions
To estimate the costs of medical care outside the DPP/
DPPOS, we assessed the mean per capita cost of hospital
days, emergency room visits, urgent care visits, out-
patient visits, calls to providers, supplies, laboratory
tests, and prescription medications within the interven-
tion groups [5]. Table 2 shows the undiscounted per
capita direct medical costs of care outside the DPP/
DPPOS. Cumulative per capita direct medical costs of
care outside the DPP/DPPOS were least for the lifestyle
group ($24,563), intermediate for the metformin group
($25,615), and highest for the placebo group ($27,468)
indicating that metformin and lifestyle participants used
fewer medical resources outside the DPP/DPPOS
interventions than participants randomized to the placebo
intervention [5]. The cumulative per-participant direct
medical costs of non-intervention-related medical care in-
creased substantially over time. The direct medical costs of
non-intervention related medical care were substantially
greater than the costs of the interventions and by 3 years,
the cumulative costs of non-intervention-related medical
care exceeded the 10-year cumulative direct medical costs
of the interventions [11]. The greater cost of non-
intervention-related medical care for the placebo group was
largely driven by greater use of outpatient and inpatient ser-
vices, prescription medications, and by the greater rate of
conversion to diabetes with the attendant costs of self-
monitoring and laboratory tests (Table 2). Across treatment
groups, the direct medical costs of non-intervention-related
medical care were 34 to 44 % higher among diabetic partic-
ipants compared to nondiabetic participants.
Total direct medical costs
By year 10, the cumulative undiscounted, per capita, total
direct medical costs of the interventions and non-
intervention-related medical care were higher for lifestyle
Table 1 Undiscounted per capita direct medical costs of the DPP/
DPPOS interventions by intervention group and study year ($)
Year Lifestyle Metformin Placebo DPP Group Lifestylea
1-DPP 1,826 584 87 898
2-DPP 887 294 50 563
3-DPP 915 299 47 590
4 (Bridge) 173 301 220 173
5-DPPOS 126 138 62 126
6-DPPOS 112 136 61 112
7-DPPOS 139 137 59 139
8-DPPOS 138 132 55 138
9-DPPOS 126 131 55 126
10-DPPOS 130 130 55 130
Total 4,572 2,281 752 2,995
aSensitivity analysis. Assumes that the core curriculum and follow-up visits
were conducted as group sessions with ten participants during the 3 years
of DPP
Table 2 Undiscounted per capita direct medical costs of care
outside the DPP/DPPOS by intervention group and study year,
and distribution of undiscounted per capita 10-year direct medical
costs of care outside the DPP/DPPOS by intervention group
and type ($)
Costs by year Lifestyle Metformin Placebo
1-DPP 1,423 1,517 1,617
2-DPP 1,780 1,837 2,045
3-DPP 1,979 1,854 2,018
4 (Bridge) 2,059 2,087 2,330
5-DPPOS 2,015 2,174 2,543
6-DPPOS 2,519 2,493 2,636
7-DPPOS 2,645 3,061 2,875
8-DPPOS 3,444 3,607 3,319
9-DPPOS 3,291 3,298 3,265
10-DPPOS 3,406 3,686 4,822
TOTAL 24,563 25,615 27,468
Costs by category Lifestyle Metformin Placebo
Outpatient visits 6,845 7,145 7,325
Inpatient care 5,631 5,817 6,856
ER visits 1,941 1,690 1,825
Urgent care visits 1,697 1,945 1,811
Calls to physicians 712 742 712
Prescription medications 6,490 6,619 6,959
Self-monitoring supplies and
laboratory tests for diabetes
1,248 1,628 1,978
TOTAL 24,563 25,615 27,468
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($29,135) than for placebo ($28,040) but were lower for
metformin ($27,896) than for placebo ($28,040). They
were also lower for the DPP group lifestyle ($27,558).
Direct Non-medical costs
Participants randomized to the three intervention
groups reported that they spent different amounts of
time attending appointments and traveling to and from
appointments, exercising, shopping, and cooking and
that they received different levels of enjoyment from
leisure-time physical activity [5, 11]. They also reported
different out-of-pocket costs related to purchases of ser-
vices and products related to physical activity and diet,
different expenditures for food, and different transporta-
tion costs [5, 11].
Diet-related costs were substantial but did not differ
among intervention groups. As might be expected, phys-
ical activity-related costs were greatest for lifestyle.
Transportation-related costs were also substantially higher
for lifestyle and metformin, due to the greater number of
study visits. Total diet-related, physical activity-related,
and transportation-related costs were greatest for lifestyle
but similar for metformin and placebo.
Participant time contributed substantially to direct
nonmedical costs. Participant time related to the inter-
ventions (time spent traveling to study visits, at study
visits, and for intervention-related calls) was greater for
lifestyle and metformin than for the placebo. Participant
time related to medical care outside of the interventions
was generally greater for placebo than for metformin or
lifestyle. Time spent shopping and cooking was the largest
component of participant time but differed little across
intervention groups. Although lifestyle subjects spent
more time exercising, the adjusted value of the time they
spent exercising was less than for either metformin or pla-
cebo because of their greater enjoyment of leisure time
physical activity and the lower opportunity cost.
The total per capita 10-year direct nonmedical costs
including the costs of participant time were lowest for
metformin ($144,143) and similar for placebo and life-
style ($147,043 and $147,493 respectively) [11].
Indirect costs
Participants in the three intervention groups reported
small differences in time lost from school, work, or usual
activities as a result of study visits, illness, or injury. In
general, participants in the placebo and metformin
groups reported more time lost than participants in the
lifestyle group [11].
Health utility scores
Every year after randomization, quality-of-life was better
for participants in the lifestyle intervention than for
those in the metformin or placebo interventions [11].
Across treatment groups, quality-of-life was worse among
participants who developed diabetes [11]. Since more pla-
cebo participants developed diabetes, the cumulative,
undiscounted, per-participant QALYs-gained over 10 years
was greatest for lifestyle (6.81), intermediate for metformin
(6.69), and least for placebo (6.67) [11].
Within DPP 3-year cost-effectiveness analysis
From the perspective of a health system and compared
to the placebo intervention, the lifestyle intervention
cost $31,500 per QALY-gained and the metformin inter-
vention cost $99,600 per QALY-gained [6]. From the
perspective of society and compared to the placebo inter-
vention, the lifestyle intervention cost $51,600 per QALY-
gained and the metformin intervention cost $99,200 per
QALY-gained [6]. The lifestyle intervention was more
cost-effective than the metformin intervention from the
perspective of both a health system and society.
Simulated lifetime cost-effectiveness of the DPP
interventions
The Fig. 1 illustrates the simulated lifetime cumulative
incidence of type 2 diabetes by intervention group based
on analysis of 3 years of data from the DPP [7]. With
the placebo intervention, approximately 50 % of partici-
pants would develop diabetes within 7 years. In contrast,
it would take approximately 18 years for 50 % of lifestyle
participants to develop diabetes and 10 years for 50 % of
metformin participants to develop diabetes. Thus, com-
pared with the placebo intervention, the lifestyle inter-
vention delayed the onset of diabetes by 11 years and
metformin delayed the onset of diabetes by 3 years. Over
a lifetime, 83 % of participants treated with the placebo
intervention would develop diabetes, as compared to
63 % of those treated with the lifestyle intervention and
75 % of those treated with the metformin intervention.
Thus, compared with the placebo intervention, the life-
style intervention reduced the absolute risk of develop-
ing diabetes by 20 % and the metformin intervention
reduced the risk of developing diabetes by 8 %. The
number needed to treat (NNT), that is, the number of
individuals that would need to be treated to prevent one
additional case of diabetes over a lifetime, was 5 for the
lifestyle intervention and 13 for the metformin interven-
tion. The relative risk reductions were 24 % and 10 %,
respectively.
Table 3 summarizes the simulated economic outcomes
from the lifetime simulation. Compared with the placebo
intervention, the lifestyle intervention cost $635 more
over a lifetime and produced a gain of 0.57 QALY [7].
The cost per QALY (Δ cost/Δ QALY) was approximately
$1100 [7]. Compared to the placebo intervention, the
metformin intervention cost $3922 more over a lifetime
and resulted 0.13 QALY-gained [7]. Thus, compared to
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the placebo intervention, the metformin intervention
cost approximately $31,300 per QALY-gained [7].
In sensitivity analyses, we found that compared to the
placebo intervention, the lifestyle intervention was cost-
saving in participants younger than 45 years of age and
cost-effective in all age groups (Table 4). In contrast, the
metformin intervention was cost-effective in the younger
age groups but cost more than $100,000 per QALY-
gained in participants 65 years of age and older. The
lifestyle intervention was cost-effective in all age groups
because it was effective in all age groups. The reduced
cost-effectiveness of the metformin intervention in the
older age groups was largely related to its reduced effect-
iveness in older participants.
If the lifestyle intervention were implemented in a
closed group of 10 patients and costs were reduced ac-
cordingly, and if the metformin intervention used gen-
eric metformin at 25 % the cost of Glucophage, the
lifestyle intervention would be cost-saving relative to the
placebo intervention and the metformin intervention
would cost approximately $1800 per QALY-gained
(Table 4). If future adherence were less than that ob-
served in the DPP and the effectiveness of the lifestyle
and metformin interventions were 20 % or even 50 %
less than that observed in the DPP, the lifestyle interven-
tion would cost $3100 to $7900 per QALY compared
with the placebo intervention, and the metformin inter-
vention would cost $38,000 to $52,600 per QALY
(Table 4). If both the lifestyle and metformin interven-
tions were implemented at lower costs, reflecting group
lifestyle classes and generic metformin pricing, and ef-
fectiveness was reduced by 20 % or 50 % relative to that
observed in the DPP, the lifestyle intervention would be
cost-saving relative to the placebo intervention and the
metformin intervention would cost approximately $6600
to $21,000 per QALY (Table 4).
10-year within DPP/DPPOS cost-effectiveness analysis
Figure 2 illustrates the effectiveness of the DPP/DPPOS
interventions as assessed over 10 years of follow-up. After
the conclusion of DPP, when all participants were offered
a group lifestyle intervention, the relative difference in the
effectiveness of the interventions decreased but the benefi-
cial effects of the lifestyle and metformin interventions
relative to the placebo intervention persisted.
Table 5 summarizes the differences in total costs and
QALYs and the incremental cost-effectiveness ratios of the
lifestyle and metformin interventions compared to placebo
over the combined 10 years of DPP/DPPOS. The incre-
mental cost-effectiveness ratio is also shown for DPP
group lifestyle intervention compared to placebo. From
the health system perspective and from the societal per-
spective, lifestyle cost more than placebo but was also
Fig. 1 Simulated cumulative incidence of diabetes among adults with impaired glucose tolerance over a lifetime
Table 3 Simulated economic outcomes in the Diabetes
Prevention Program intervention groups over a lifetimea
Outcome Lifestyle
intervention
Metformin
intervention
Placebo
Intervention
Lifetime intervention costs, $ 9,718 8,801 2,907
Lifetime outcome costs, $ 42,256 46,460 48,432
Total lifetime direct medical
costs, $
51,974 55,261 51,339
Lifetime QALYs 10.89 10.45 10.32
Δ Cost vs. placebo, $ 635 3,922 —
Δ QALY vs. placebo 0.57 0.13 —
Δ Cost / Δ QALY, $ 1,124 31,286 —
QALY quality-adjusted life-year
aCosts and QALYs discounted at 3 % per year
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more effective as assessed by QALYs-gained. From a
health system perspective, with both costs and health out-
comes discounted at 3 % per year, the cost of the lifestyle
intervention compared to the placebo intervention was
approximately $12,900 per QALY-gained. In contrast,
from a health system and societal perspective, metformin
had slightly lower costs and nearly the same outcome (as
assessed by QALYs) as placebo. The DPP group lifestyle
intervention cost approximately $1500 per QALY-gained
from a health system perspective and $8400 per QALY-
gained from a societal perspective after discounting.
Conclusions
When a new treatment is cost-saving - that is, more effect-
ive and less costly than usual care, it should be widely
adopted and used. Unfortunately, fewer than 1 in 5 new
treatments in health and medicine is cost-saving compared
to usual care [15]. Published cost-effectiveness ratios, that
is the cost in dollars per QALY-gained for prevention and
treatment range from less than $10,000 per QALY-gained
to greater than $1 million per QALY-gained with most fall-
ing between $10,000 and $50,000 per QALY-gained [15].
While influenza immunization has been demonstrated to
be cost-saving in the Medicare population, interventions
such as mammography, antihypertensive treatment, and
cholesterol treatment for secondary prevention of cardio-
vascular disease have been estimated to cost between
$10,000 and $60,000 per QALY [16]. Widely implemented
interventions such as dialysis for end-stage renal disease
($50,000 to $100,000 per QALY) and left ventricular assist
devices ($500,000 to $1.4 million per QALY) are substan-
tially more expensive [15, 16].
From the perspective of a health system or society,
what is the value of delaying or preventing the development
of type 2 diabetes? From a health system perspective,
it delays or prevents the direct medical costs of dia-
betes including the costs of diabetes education and nu-
tritional counseling, glucose monitoring, antihyperglycemic
Table 4 Simulated economic outcomes in the Diabetes Prevention Program intervention groups over a lifetime: Sensitivity analyses
Variable Lifestyle Intervention vs. Placebo Intervention Metformin Intervention vs. Placebo Intervention
Δ Cost, $ Δ QALYa Δ Cost/Δ QALY, $ Δ Cost, $ Δ QALYa Δ Cost/Δ QALY,$
Base-case analysis 635 0.57 1,124 3,922 0.13 31,286
Age 25–44 y −395 0.63 Cost-saving 2,574 0.27 9,573
Age 45–54 y 489 0.63 781 4,024 0.13 30,013
Age 55–64 y 1,807 0.53 3,409 4,413 0.07 64,904
Age 65–74 y 2,617 0.39 6,646 4,119 0.02 173,593
Age≥ 75 y 2,508 0.21 11,700 3,255 0.01 273,207
Reduced costb -3,696 0.57 Cost-saving 220 0.13 1,755
20 % reduced effectiveness 1,417 0.46 3,102 4,084 0.11 38,145
50 % reduced effectiveness 2,371 0.30 7,886 4,307 0.80 52,562
Reduced costb and 20 % reduced effectiveness -2,181 0.41 Cost-saving 635 0.10 6,576
Reduced costb and 50 % reduced effectiveness -348 0.23 Cost-saving 1,198 0.06 20,994
aQALY quality-adjusted life-year
bAssumes that lifestyle intervention is implemented in a closed group of 10 patients and that metformin intervention is implemented with generic metformin
Fig. 2 Observed cumulative incidence of diabetes among adults with impaired glucose tolerance over the combined 10-years of DPP/DPPOS
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treatments, and surveillance and treatment of complica-
tions and comorbidities. From a societal perspective, dia-
betes prevention also reduces costs to the individual not
reimbursed by the health system and time lost from work
and usual activities. It also improves quality of life.
The direct medical costs of diabetes are enormous.
The American Diabetes Association estimated that total
per capita healthcare expenditures for people with dia-
betes are approximately $13,700 per year, of which,
$7900 is attributable to diabetes [17]. This estimate likely
overstates the costs of diabetes in DPP participants with
diabetes since they were actively diagnosed, very early in
their clinical course, and had few complications or co-
morbidities. In 2000, using data from a single managed
care health plan, we estimated that the median, annual,
direct medical cost of care for a man with diet-
controlled type 2 diabetes with no microvascular, neuro-
pathic, or cardiovascular risk factors or complications
was approximately $1700 [13]. More recently, using data
from approximately 7100 type 2 diabetic patients en-
rolled in 8 managed care health plans participating
across the United States, we estimated that the mean,
annual, per capita, direct medical costs of care would be
approximately $2500 for a man with recent onset dia-
betes without complications or comorbidities [18]. These
costs of uncomplicated type 2 diabetes are quite consist-
ent with those observed during DPP/DPPOS. Compared
to the substantial costs of diabetes, the costs of the life-
style, metformin and DPP group lifestyle interventions
were quite small.
During DPP and DPPOS, the costs of the lifestyle and
metformin interventions were greater than the cost of
the placebo intervention, but the cumulative, undis-
counted, per capita costs of the lifestyle and metformin
interventions were small in comparison to the cost of
nonintervention-related medical care (medical care re-
ceived outside the DPP/DPPOS). Indeed, within 3 years,
the cumulative undiscounted costs of nonintervention-
related medical care exceeded the 10-year cumulative
direct medical costs of the lifestyle and metformin inter-
ventions. Within 10 years, the total, cumulative, undis-
counted costs of the interventions and nonintervention-
related medical care were only slightly higher for lifestyle
than placebo and lower for metformin than placebo.
With respect to the cost-effectiveness of diabetes pre-
vention, it is now clear that our use of a 3-year time hori-
zon in our within-trial economic analysis [6] resulted in a
higher cost per QALY-gained than the analyses which
used a lifetime or a 10-year time horizon. With a three-
year time horizon, treatment costs were higher and the
benefits of the lifestyle and metformin interventions were
less. The costs of both the lifestyle and metformin inter-
ventions were greatest in year 1, decreased substantially in
years 2 and 3 and decreased further during years 4
through 10. In contrast, much of the benefit of the lifestyle
and metformin interventions, as assessed by both cumula-
tive, non-intervention-related direct medical costs and
quality-of-life, occurred after three years of follow-up. The
results highlight the importance of adopting a longer time
horizon when assessing the impact of an intervention for
a chronic disease.
The results of the 10-year within trial economic ana-
lysis of DPP/DPPOS support the results of our lifetime
simulation. In the lifetime simulation, from the perspec-
tive of a health system, both the lifestyle intervention
and the metformin intervention were cost-effective, and
the results were robust to plausible changes in interven-
tion cost and participant adherence. In the 10-year
within trial economic analysis, lifestyle was cost-effective
and metformin was marginally cost-saving or at least
cost neutral compared to placebo.
There are at least two limitations to the 10-year
within-trial analysis which might, in part, explain the dif-
ference between it and the results of our lifetime simula-
tion. First, DPPOS was an observational follow-up of
DPP, a randomized controlled clinical trial. It is likely
that during DPPOS, when 57 % of placebo participants
attended at least one group lifestyle intervention session,
the placebo intervention was more effective than “usual
Table 5 Differences in total costs and QALYs and incremental
cost-effectiveness ratios for lifestyle and metformin vs placebo
over 10 years
Differences in costs (Δ cost ) Lifestyle
vs placebo
Metformin
vs placebo
DPP group
lifestyle vs
placeboa
Health system perspectiveb
Undiscounted 1,656 −251 $81
Discountedb 1,748 −205 $201
Societal perspectived
Undiscounted 2,572 −3,644 $996
Discountedb 2,688 −3,021 $1,141
Differences in QALYs (Δ QALY)
Undiscounted 0.15 0.01 0.15
Discountedc 0.14 0.01 0.14
Health system perspectiveb
Undiscounted 10,759 Cost-saving $528
Discountedc 12,878 Cost-saving $1,478
Societal perspectived
Undiscounted 16,699 Cost-saving $6,468
Discounted 19,812 Cost-saving $8,412
aSensitivity analysis. Assumes that the core curriculum and follow-up visits
were conducted as group session with ten participants during the 3 years
of DPP
bIncludes total direct medical costs
cBoth costs and QALYs discounted at 3 %
dIncludes direct medical costs, direct nonmedical costs including participant
time, and indirect costs
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care”. Thus, if real-world usual care were used for com-
parison, the difference in effectiveness between the life-
style and placebo interventions might have been greater.
Second, in our analysis of the DPP group lifestyle inter-
vention, we assumed that lifestyle could be implemented
in a group rather than individual format at one-third
lower cost and achieve the same outcomes. Although
group-implemented lifestyle interventions have been
shown to be at least as effective as individual programs
for weight loss, there has not been a direct comparison
of individual and group lifestyle interventions for dia-
betes prevention.
Taken together, these analyses demonstrate that although
more expensive, lifestyle intervention, when compared to
placebo, is cost-effective, and generic metformin when
compared to placebo is cost-effective or even cost-saving
from a health system and societal perspective. If a DPP
group lifestyle intervention could be delivered at 1/3 lower
cost than the DPP lifestyle intervention and achieve the
same outcomes, it might also be cost-saving compared to
placebo.
The challenges associated with motivating a racially
and ethnically diverse population to take up and main-
tain the weight loss and physical activity goals of the
DPP over the long term should not be underestimated.
Nevertheless, flexible interventions delivered by skilled
lifestyle coaches that accommodate individual prefer-
ences and reflect local community and cultural contexts
may achieve these goals [19–21]. In conclusion, these
economic analyses should assist health plans and policy
makers in comparing the benefit of diabetes prevention
to other preventive and palliative interventions. The
adoption of diabetes prevention programs by health
plans and society will result in important health benefits
and represents a good value for money.
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